-+ 0.00%
-+ 0.00%
-+ 0.00%

TOMI Environmental (TOMZ) Q3 2026 Earnings Call Transcript

The Motley Fool·11/16/2026 22:13:07
Listen to the news
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Thursday, Nov. 12, 2026

CALL PARTICIPANTS

  • Chief Executive Officer and Chairman - Dr. Halden Shane
  • Chief Operating Officer - Elissa Shane
  • Chief Financial Officer - Niroshan Srirathan

TAKEAWAYS

  • Net Sales -- $2.49 million, representing 24% growth driven by stronger commercial execution and improved equipment sales.
  • Operating Income -- $30,047, representing the first positive quarterly result since the third quarter of 2024.
  • Gross Profit -- $1.47 million, increasing 19% reflecting higher volume and product mix.
  • Gross Margin -- 59.0%, compared to 61.2% in the prior-year quarter.
  • Product Revenue -- $2.08 million, growing 30% due to increased demand for SteraMist systems and applicators.
  • United States Revenue -- $1.92 million, increasing 50% reflecting expanded domestic sales activities.
  • Operating Expenses -- $1.44 million, representing a 7% decrease driven by reduced general and administrative costs and disciplined overhead management.
  • Total Sales Pipeline -- $35 million, representing potential future revenue across all stages of the sales process.
  • Sales Backlog -- $2.8 million as of the call date, increasing from $2.5 million at the end of the third quarter.
  • Mobile Equipment Growth -- 107% increase year-to-date when including open orders compared to the full-year 2025 total.
  • Nine-Month Revenue -- $6.39 million, representing a 38% increase compared to the first nine months of 2025.
  • Nine-Month Product Revenue -- 61% growth year over year, driven by capital equipment sales.
  • Working Capital -- $1.95 million, rising from $1.02 million at the end of fiscal 2025.
  • Debt Conversion -- $2.5 million in convertible notes converted during the quarter, reducing debt obligations and future cash interest commitments.
  • Expected Purchase Orders -- $5 million in orders anticipated before the end of 2026 across multiple accounts.
  • Late-Stage Deal Pipeline -- $8.5 million to $10 million, representing active accounts with set deadlines for purchase order receipt.
  • Enclosure Sales -- $2.3 million year-to-date, reflecting growth in custom engineered and integrated system opportunities.
  • Service and Support Sales -- $1.7 million year-to-date, representing a 133% increase compared to full-year 2025 levels.
  • Shareholder Equity -- $3 million to $4 million expected as of Sept. 30, 2026.
  • International Revenue -- $572,000, representing a 22% decrease.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Shane stated, "A production change at one large customer that no longer requires decontamination services has weighed on our year-over-year comparison in service revenue," noting the impact of customer churn on segment growth.
  • Management noted, "The company and its independent registered public accounting firm have not yet completed the review of the accounting treatment for the company's convertible notes," indicating that current financial figures are subject to change.
  • Dr. Shane stated, "Working capital has always been an issue with the company having enough for the growth we see," indicating potential constraints on future expansion.

SUMMARY

TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) returned to positive operating income in the third quarter of 2026. Management reported sequential revenue growth throughout the fiscal year, supported by increased demand in the life sciences segment and mobile equipment sales. The company reported a multimillion-dollar sales pipeline and backlog as of the call date. The quarter included a significant reduction in debt obligations and expanded regulatory registrations for food safety applications.

  • CEO Shane stated, "Third quarter revenue now stands approximately 51% above the first quarter," highlighting the sequence of growth throughout the 2026 fiscal year.
  • Management emphasized the adoption of the "razor/razor blade model" by identifying the applicator as a core component used to drive recurring BIT Solution sales.
  • COO Shane noted that the company engaged a new technical lead for food safety and reported an average Listeria reduction of greater than 7 logs in independent studies.
  • The company expects to receive $5 million in purchase orders before year-end, which includes two large-scale custom engineered systems scheduled for 2027 installation.
  • Management reported that BIT Solution sales year-to-date have already surpassed the total sales for the entirety of the previous year.
  • The company expanded its presence in the defense sector with approvals from contractors in Korea and defense agencies in Canada.

INDUSTRY GLOSSARY

  • BIT: Binary Ionization Technology, a hydrogen peroxide-based decontamination platform.
  • iHP: Ionized Hydrogen Peroxide, the fog produced by BIT used for germ-killing.
  • SIS: SteraMist Integrated System, a standardized platform for facility decontamination.
  • CES: Custom Engineered System, a bespoke configuration for specific industrial or healthcare needs.
  • HACCP: Hazard Analysis and Critical Control Points, a management system in which food safety is addressed through the analysis and control of biological, chemical, and physical hazards.
  • FSIS: Food Safety and Inspection Service, the agency of the United States Department of Agriculture responsible for inspecting meat and poultry.
  • AgriMist: A SteraMist product line specifically registered for post-harvest food safety and agricultural use.

Full Conference Call Transcript

Operator: Good day, everyone. Welcome to TOMI Environmental Solutions, Inc. Third Quarter 2026 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, John Nesbett at IMS Investor Relations. The floor is yours.

John Nesbett: Thank you for joining us today for the TOMI Environmental Solutions Investor Update Conference Call. On today's call are TOMI's Chief Executive Officer and Chairman, Dr. Halden Shane; Chief Operating Officer, EJ Shane; and our Chief Financial Officer, Niroshan Srirathan. A telephone replay of today's call will be available through November 19, 2026, the details of which are included in the company's press release. A webcast replay will also be available at TOMI's website, www.steramist.com. Certain written and oral statements made by management of TOMI may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.

These forward-looking statements should be evaluated in light of important risk factors that could cause actual results to differ materially from our anticipated results. The information provided in this conference call is based upon the facts and circumstances known at this time. Please refer to our filings with the SEC for a discussion of these risk factors. The company undertakes no obligation to update these forward-looking statements after the date of this call. I will now turn the call over to TOMI's Chief Executive Officer and Chairman of the Board, Dr. Halden Shane. Please go ahead.

Halden Shane: Thank you, John, and thank you all for joining us today. What a day it is. We delivered another consecutive quarter of sequential revenue growth, extending the upward trend we have maintained throughout 2026. Revenue increased approximately 36% from the first quarter to the second and a further 11% from the second quarter to the third. Third quarter revenue now stands approximately 51% above the first quarter. This is a steady sequential progress built across the year, not a 1 quarter result. We generated positive operating income for the first time since the third quarter of 2024. The strategic initiatives we have implemented are working. Revenue for the third quarter of 2026 was approximately $2.49 million.

That's up about 24% from the $2.01 million in the third quarter of 2025. And as stated, 11% from the $2.25 million last quarter. Our sales order backlog is approximately $2.5 million as of September 30, and has since increased to approximately $2.8 million. The company expects shareholder equity at September 30, 2026, to be in a range of $3 million to $4 million. The company and its independent registered public accounting firm have not yet completed the review of the accounting treatment for the company's convertible notes, including the conversion of $2.5 million of notes during the third quarter.

Accordingly, we will not review the financial results that may be affected by that review, including any gain or loss associated with the conversion, net loss, net loss per share and the related liability and stockholders' equity balances. Based on the information currently available, we expect any impact from this accounting treatment to be a noncash and the company does not expect the review to affect the revenue, gross profit, operating expense or income from operation figures. However, all the results remain subject to change until the company files its quarterly report on Form 10-Q for the period ended September 30, 2026. BIT Solution demand is showing steady increase as well this year.

Delivered BIT Solutions sales year-to-date together with orders that remain open have already surpassed BIT Solution sales for all of last year, as we reach that mark with 2 months still ahead of us. Service continues to trend higher. The sharpest break from recent years is mobile equipment. Mobile equipment year-to-date, together with open orders, is above last year's full total by almost 107%. For the past 2 years, we have said that continuous growth depends on each of our departments rising together, not 1 or 2 of our offerings carrying the year. We expect 2026 to end on that basis, providing us good visibility into near-term revenue.

We are continuing our razor/razor blade model and the applicator is now a core part of it. The applicator is the component that enables iHP, whether it's paired with a mobile system or installed in a permanent or semi-permanent configuration. We began emphasizing the strategy less than 2 years ago as an extension of our consumable-driven model. It, of course, has a longer replacement cycle than BIT Solution, but a much shorter sales cycle than full capital equipment. So it generates revenue and margin now while it supports recurring BIT Solution demand down the road. Our current sales opportunity pipeline is projected value of approximately $35 million.

It includes opportunities at every stage of the sales process from proposals to negotiations to purchasing and is supported by continued growth in integrated system opportunities involving our SteraMist Integrated System platform or SIS, hybrid and Custom Engineered System or CES configurations. I want to be clear that these represent potential future revenue. They're not committed orders yet or guarantees of future performance. We remain focused on our goal of $12 million in sales for 2026. Our sales team is small, but is dedicated and is working hard to reach that benchmark. On the cost side, our disciplined overhead management continues to pay off.

Operating expenses for the quarter were approximately $1.44 million, down 7% from a year ago, led by savings in general and administrative costs. And working capital increased to approximately $1.95 million, up from $1.02 million at the end of 2025. Now let me update you on several last quarter items. First, the nearly $1 million project we introduced last quarter, adding applicators into proprietary machine lines at a major multinational health care manufacturer is underway. And that customer is now expanding into additional facilities, taking advantage of our recently received European Union regulatory acceptances. TOMI continues to expand its presence in the defense sector.

Following approvals from defense contractors in Korea and defense agencies in Canada, we've developed a very detailed strategic plan for these accounts and have provided 1 of the 2 agencies with systems that are ready to be deployed. TOMI iHP Corporate Service continues to grow. We now have contracted decontamination service engagements with customers, including Integra Pharma, Catalent, Cleveland Clinic and LFB USA, and our team is providing on-site support about 4 times a month, including at the Centers for Disease Control and Prevention in Atlanta.

A production change at one large customer that no longer requires decontamination services has weighed on our year-over-year comparison in service revenue, but we have partially offset that impact, and we are actively expanding our service deployment business, including pathways to deliver Corporate Services directly to the end users internationally. In the third quarter, we continue to add partners. SteraMist iHP activity across the Americas increased in life sciences, food safety and health care. We brought on additional partners in Mexico and a new one in Argentina, while we completed further business in India and the European Union. We continue to work with our legacy partner in Mexico on our previously announced cheese factory.

That work is still generating strong data on extending the shelf life of cheese, and we have expanded it into other food groups and applications with them. [ Older ] the customers, including Thermo Fisher, continue to expand capital equipment purchases. We also expanded our relationship with a leading global eye health company. This customer, onboarded in 2025 at 2 locations, placed an additional equipment order late into quarter 3. Combined revenue for the 2 sites is approximately $750,000, and they have a recurring BIT Solution agreement with TOMI. Further orders at both facilities, additional equipment systems and a Custom Engineered System for integrated automated decontamination are still prospective.

We anticipate that some or all of them could be received before year-end in a range of approximately $960,000 to $1.7 million. We are putting resources behind the pipeline and behind customer requirements across our product and service line. We expect that focus to hold through the close of the year, and we look forward to reporting our 2026 finishes. I'm going to now turn the call over to our Chief Financial Officer, Niro Srirathan, for a review of TOMI's third quarter financial results.

Niroshan Srirathan: Thank you, Dr. Shane. Q3 marked an important financial inflection point for TOMI. Revenue increased 24% year-over-year and 11% sequentially to approximately $2.49 million compared with approximately $2.01 million in Q3 2025 and $2.25 million in Q2 2026. We generated approximately $30,000 of positive operating income, our first positive quarterly operating result since Q3 2024. Revenue growth was led by product sales, which increased approximately 30% year-over-year to approximately $2.08 million compared with approximately $1.6 million in Q3 2025. U.S. revenue increased 50% to approximately $1.92 million. For the first 9 months of 2026, total revenue increased 38% to approximately $6.39 million, including 61% growth in product revenue.

Gross profit increased 19% year-over-year to approximately $1.47 million compared with approximately $1.23 million in Q3 2025. At the same time, operating expenses declined 7% to approximately $1.44 million from approximately $1.55 million, including a significant year-over-year reduction in general and administrative expenses. This combination of higher revenue, increased gross profit and disciplined expense management resulted in approximately $30,000 of positive operating income compared with operating losses of approximately $321,000 in Q3 2025 and $244,000 in Q2 2026. Importantly, we achieved this despite continued elevated professional and consulting costs associated with strategic and financing activities. Overall, Q3 demonstrated meaningful progress across the business, double-digit revenue growth, positive operating income and substantially improved operating income.

We believe these improvements provide a stronger financial foundation entering Q4. I will now turn the call over to our Chief Operating Officer, EJ Shane, for an update on our commercial priorities and outlook for the remainder of the year.

Elissa Shane: Thank you, Niro. It has been a busy year, and the work ahead is both commercial and operational. For the most part of the year, we have maintained a full pipeline of $35 million and an active pipeline, meaning those considered late-stage deals and expected to close in the near term, of $8.5 million to $10 million, while, of course, fulfilling and receiving orders for the current standing $9.3 million revenue plus open book sales for 2026. We expect to receive approximately $5 million in purchase orders before year-end.

Because the hybrid and the SIS platform is more standardized product grouping, it has reduced the need for fully custom enclosure builds and made it easier to retrofit iHP into equipment our customers already own. And as Dr. Shane referenced, we are experiencing growth across all our key offerings. The company has also had a heavy focus on manufacturing upgrades, internal compliance, safety and quality controls and the regulatory affairs, the latter of these driven mainly by the interest in our Food Safety Division. On the regulatory side, we continued to strengthen our registration portfolio and made further progress toward NSF certification for biosafety cabinet decontamination.

During our last meeting in October, I volunteered to help rewrite the revision to that standard, which gives TOMI a direct voice in how it takes shape. Food Safety is not yet a driver in our revenue results, but it has been a regulatory focus. To support our work in meat and ready-to-eat applications, we engaged Josh Hasty, PhD CEO of FH Services. Dr. Hasty was Director of Food Safety and Quality Assurance and Director of R&D at Tyson Foods' Ingredient Solutions Group and a technical lead on Cargill's McDonald's Beef program. He brings deep industry expertise to our Food Safety initiatives.

On October 15, we announced an independent laboratory study showing that SteraMist iHP sharply reduced a specific type of Listeria, a food-borne pathogen that can grow under refrigeration. On flat surfaces, treated samples showed an average reduction of greater than 7 logs at or below the lab detection limit. In processing facilities, this type of Listeria often forms a biofilm, a protective layer that lets it cling the surfaces and survive routine sanitization. Food Safety is a priority growth market for TOMI, and this independent data gives our sales team and partners validated evidence for food processors.

In dairy and infant formula, our work with Nestle and Danone continues as we pursue the applicable international registrations and food contact notifications with the FDA. Nestle has added additional locations, thus further registrations have been submitted worldwide. We also continued related work with another nutritional company and received initial testing data this past quarter. We are working with this company in their domestic facilities seeking the use of iHP with international locations to follow suit. Their use depends on FDA acceptance. Submissions have been completed, and this customer is assisting us in gathering the additional evidence required. All 3 of these companies are in it for the long haul.

They understand the regulations, they want SteraMist iHP, and they are working with us to obtain the required authorizations. This effort is very active. There is a specific strain of Clostridium, which is one of the most significant contamination control challenges in infant formula. The issue is not the organism is particularly difficult to eliminate. It is compatibility and regulatory hurdles in the manufacturing environment. Effective control requires sporicidal level efficacy plus approval for food contact surfaces, no-rinse requirement and compatibility with dry manufacturing environments. That combination has historically been very difficult to meet. That is the opportunity we see for SteraMist iHP. We are working with some of the largest names in infant formula to address it globally.

Beyond infant formula, we see a broader opportunity in food processing. Sterilization-level microbial reduction that stays compatible with food contact surfaces and with food manufacturing requirements, including ready-to-eat facilities, where contamination control is critical and daily disinfection is part of operation. The opportunity is reoccurring. Food manufacturers run daily cleaning procedures, not onetime disinfection. Integrating the technology into those procedures can mean consistent high-volume product use. We are already seeing that with several food manufacturers where repeatable protocols support ongoing product consumption. As we work through the regulatory requirements to expand these applications, we believe Food Safety can become one of the most significant growth verticals for SteraMist iHP.

Once that pathway is established, we believe the addressable opportunity in food processing and Food Safety could exceed anything we have pursued in other industries. This is not another disinfection product. It is a response to a substantial largely unmet need with technology that can become part of everyday disinfection. In summary, in Food Safety, we have narrowed our focus within the broad market and all within the market of food processing, meat and ready-to-eat, general nutritional products, dairy and infant formula and poultry. For poultry and related food contact use, hydrogen peroxide may qualify under a very specific 21 CFR section, but only under specified conditions. That regulation does not establish the status of the complete SteraMist formulation.

Each component and each intended use still needs its own lawful FDA basis, whether an applicable regulation, a food contact notification or another recognized pathway. We do not yet have poultry use residue data sufficient to support a nondetectable residue claim. We are developing that data now and determining the applicable regulatory path. FSIS is the USDA agency that inspects meat and poultry plants. Thus, in the short term, we have filed an FSIS new technology notification as the technology supplier, seeking a no-objection letter.

This letter unfortunately, would not establish antimicrobial efficacy and would not by itself allow the use of iHP, but it would provide each establishment the ability to validate iHP in its own process and HACCP system or hazard analysis and critical control points. The Food Safety system an inspected plant must use to identify hazards and control them in its own process. In health care, special pathogen units remain an important area for us. These units manage high-consequence infectious diseases and require rapid validated and comprehensive decontamination of rooms, equipment and personal protective equipment. We saw growing adoption through the first half of 2026, and the first NV+ was delivered to one of these units.

In October, we also confirmed that we're ready to support increased requests for preparedness planning, equipment and decontamination services with systems ready to deploy, our on-site service team and our global partner network. The Democratic Republic of the Congo is experiencing its 17th Ebola outbreak. The CDC describes it is spreading substantially faster than previous Ebola outbreaks and is the second largest on record. It passed 1,000 confirmed cases within 40 days of responsive activation. The 2018 DRC outbreak took about 235 days to reach more than 1,000 cases. Cases have also been reported in Uganda, Kenya and Nigeria.

Through contacts in our customer base and a long-standing partner in Angolia (sic) [ Angolia ], who continues to experience high rates of mpox, we are in discussions with the Africa Centers for Disease Control and Prevention about possible support for response efforts. There is enough interest in front of us that we expect it to support sales over the coming years. Now narrowing to the remaining months of 2026, the Life Sciences remains our largest division for the time being. It includes pharmaceutical manufacturers, universities, research laboratories as well as health care product manufacturers. Delivered sales plus open orders for 2026 stand at $9.3 million.

Separate from that figure, we expect approximately $5 million in additional purchase orders before year-end. Within that $5 million, and as Dr. Shane previously referenced, we expect the customer to order more than $1 million in a mix of mobile capital equipment and a custom engineered system. The remainder of this project includes expansion orders from 6 other customers for either mobile capital equipment or iHP deployment service work and a second large-scale custom engineered system. Those 2 systems are scheduled for installation in February and April 2027. The year is ahead of last year because revenue has grown quarter-to-quarter.

Mobile capital equipment demand is running well above 2025, while our other offerings continue to increase at a steady pace, and established customers continue to expand their use of SteraMist iHP. Life Sciences remains the core of the business. Food Safety is moving forward on its regulatory path, and I'll keep you current as that work develops. The pipeline is held. We expect to finish the year in line with what analysts have reported and installations are already scheduled for early 2027. I thank you all for your time this afternoon. I will now return the call back to our CEO, Dr. Halden Shane.

Halden Shane: Thank you, EJ. Good report. TOMI has been built with limited capital and a small team similar to how Apple started, guided by a clear purpose, to be #1 and SteraMist is the company that modernized the 40- to 50-year-old technology that are used for disinfection and decontamination. SteraMist has certainly matured. It is now being adopted by many of the largest companies in the world as a replacement for the 40-, 50-year-old legacy technologies, and it is increasingly used by major food groups, both nationally and internationally. As EJ noted, there are regulatory steps we need to complete, and we are actively working through them.

If we are successful, and we believe we will be, SteraMist could become a leading technology in Food Safety, food packaging, food security and food transportation. And we also believe it may help extended the shelf life of many foods. SteraMist has a pipeline that's $35 million and is growing every week as we know our product is in extreme demand. The application for this product is endless, whether it's curing a worldwide problem of killing the mite affecting honeybees or biodefense weapon used in drones. We know we have positioned ourselves to be in the battle of controlling pathogens of all types around the world in and outer space.

Looking ahead, we think that our goal is to build towards steadier, more predictable performances. I think that the unevenness and the lumpiness of this company is over. We have some hurdles to work through, but we're doing them, and we're moving the company forward to sustained profitability ongoing into the near future. I want to thank most of my staff for doing a splendid job in accomplishing these goals. This is a small company with a big heart, but a great product. Thank you to our investors, bankers, partners and customers, from Fortune 500 companies to smaller organizations, for your continued support.

We remain focused on delivering mission-critical results as we work to build our position in the disinfection and decontamination market and to help make the world a safer place to live and work. We look forward to updating you on our progress. Thank you, and have a good morning, afternoon or evening depending upon where you are listening from. Operator, open the call to questions.

Operator: [Operator Instructions] Your first question is coming from Amit Dayal with H.C. Wainwright.

Amit Dayal: Congrats on the quarter, guys. It looks like the execution is starting to come through. Just one question on the purchase order for this $5 million purchase order. Is this expected to be delivered over the next 6 months or sooner? Like how should we think about recognizing revenues from this purchase order?

Elissa Shane: Sure. So the $5 million is across a few different accounts. It's not just one purchase order. 2 of them are custom engineered systems. So 2 that are within that $5 million will be delivered in the first quarter and some in the second quarter of next year. But a good amount of them are mobile pieces of equipment Environment Systems.

Amit Dayal: And then of the $35 million in the pipeline, are these high-probability, sort of, discussions you're having with the customers? Just want to get a sense of how that could develop into purchase orders and actual revenues?

Elissa Shane: Of course. I mean the high probability are within that $12 million mark, right? That's, kind of, how we've been reporting all year and are the active accounts where we have deadlines set for when purchase orders will be received. The $35 million is our entire database, which keeps maintaining itself as such even as orders are delivered. The probability within that $35 million varies from account to account. But as Food Safety is picking up and the customers are working with us on these regulatory affairs, I expect it to continuously increase substantially.

Amit Dayal: Understood. And on the service revenue side, we saw this 1% growth. Is this -- should we assume that this should be tied to the product sales that are ongoing? Or do you see a path for service revenues to accelerate a little bit going forward?

Elissa Shane: I believe IHP deployment service revenue, you'll start to see increase going forward, especially as we start to work with partners and deploy internationally because we're getting quite a few of those requests. Our service financial reports also do include our support services, which is about 10 different offerings that we can help customers on. So that's the -- it definitely will continue to increase as our build-ins and our integration and stand load items get implemented in these facilities.

Amit Dayal: Understood. Just last one for me. On the working capital side, are we constrained a little bit to execute on the growth mandate because of what the working capital setup is? And how are you sort of going to manage through that?

Halden Shane: So working capital has always been an issue with the company having enough for the growth we see. We're currently discussing with multiple facilities to expand a credit in these areas or do a pipe type offering going forward. So we feel that with our deposits that come in on these large accounts, which is about 50% at times, we're able to handle the capital moving forward.

Operator: Your next question is coming from Todd Felte with StoneX Wealth.

Todd Felte: Congratulations, [ Boh ], to you and your team on achieving the positive operating income. I know you worked hard for that. Just had a couple of questions referring to some events that EJ spoke of. The first was the Tyson, Cargill study with an independent result basically stating that SteraMist was the best option. Have either of those companies contacted you since that study? And are you in negotiations with them?

Elissa Shane: Yes, we are. We're in communication with them through our new partner, Josh, who knows them incredibly well. So it's just a matter of establishing cleaning protocols with companies such as Tyson and the like.

Todd Felte: And I know it's -- you're probably not able, but is there any way you can quantify what maybe orders from those type of companies would be?

Elissa Shane: Yes, a little too early. The study was just completed in October, but as we continue to build our evidence base of IHP within the food industry on top of the regulating affairs that we're pursuing, then it's -- it will be very large. It's just -- I can't quantify it at the exact moment. But there is interest, and we are in communication with quite a few. And it's not just 1 or 2 facilities. It's -- they're looking at it as a standard for all their locations. So I can report on that.

Todd Felte: Okay. And on those food safety studies, if you're able to use SteraMist directly on the food products, would SteraMist have been able to prevent the lettuce cyclospora recalls that we all saw in the news over the last couple of months?

Elissa Shane: Yes.

Todd Felte: Okay. One other news item that I was hoping you could address. There was a huge article on an FDA warning letter to Baxter that they issued on September 29 when they detected a lot of contamination through their production facilities. Has Baxter reached out to you for any work with them?

Elissa Shane: We are very familiar with the FDA warning and are aware of the issues that Baxter is currently looking to fix.

Todd Felte: Okay. I didn't mean to put you on the spot. Finally, last easy question. With the estimate of the significantly increased revenue and after achieving positive operating income in this quarter, do you expect to have, given your razor-razor blade model, positive earnings per share and operating income in quarters moving forward consistently?

Niroshan Srirathan: Yes, Todd. I think, yes, the way we are going now, especially from a two-pronged fact, we're definitely improving our revenue. So we're expecting our gross profit to be increasing going forward. And yes, we're tightening our operating expenses. And also, with now the conversion of the note holders, our interest expense will be dropping as well. So anticipating from a profitability going forward.

Todd Felte: Okay. So I can expect positive EPS in all future quarters? At least I hope, right?

Halden Shane: We all do.

Operator: [Operator Instructions] Your next question is coming from John Nelson.

John Nelson: Congratulations on the quarter and the very thorough update. I have several questions. And the -- let's see. The projection for $12 million in revenues would result in you having a monster fourth quarter, and that is very exciting, and thank you for the detail on that. The big increase in closure orders you cite in the press release year-to-date, what kind of time span are those expected to be filled on those orders?

Elissa Shane: Sure. I mean we have quite a few projects currently being built that will be delivered before the end of the year. And then the 2 that were referenced within the $5 million book of business that we're expected to receive purchase orders for, one is set for delivery in February and another is set for delivery between March and April.

John Nelson: Okay. Great. And let's see, are you, at this time, talking to any parties directly on the autonomous vehicle drone platforms or robotic systems?

Halden Shane: We're not in any specific negotiations, but the concept is very doable. And especially with the marketplace and where it's headed with autonomous vehicles, it seems to be the wave of the future for this type of technology in those industries.

John Nelson: Okay. And then earlier in the quarter, you mentioned the participation in Project MEND -- with Project MEND. And is that -- is the goal on that to achieve some penetration on replacing ethylene oxide for medical instrument sterilization? Or can you explain a little bit more about that?

Elissa Shane: Sure. Project MEND is a group that we're working with to sterilize medical equipment as they recycle them for certain health care groups. So as patients require wheelchairs or different other medical items, they're spraying it and using SteraMist on them and then labeling it with our sticker if this has been sterilized with SteraMist IHP. So it's a little bit of a way of a brand awareness for health care environments and being used, and they're very active at shows and promoting our product, which has been nice. So it's more of a health care in general.

John Nelson: Yes. Has there been any progress on or new developments as far as your work -- the company's work on trying to penetrate the ethylene oxide market for sterilization of medical instruments?

Elissa Shane: Yes, there still is -- that still falls under the FDA and the 510(k) clearance that we're still seeking. Our partners with the chambers are developing studies and providing data that's required for that part of FDA. So working with all these agencies in tandem with all the regulatory affairs is all happening simultaneously. It just all takes time.

John Nelson: Okay. And then you signed in the press release the EPA's unconditional registration on AgriMist usage on post-harvest food safety. And you also mentioned it hasn't impacted sales results yet, but I was just wondering how long you think the lag might be between the actual sales being generated from that category.

Elissa Shane: Sure. I mean sales are being generated in food safety. So we are selling our handheld equipment and gaining these cleaning protocols with certain facilities. I think the majority of the bulk and the change that we're going to see is when we're able to create a standard with it. Unfortunately, the AgriMist EPA label was a great win and is used, but we also need the FDA, USDA, [ SSIs ]. I feel like food is related around almost every agency we have here, and we're working with them all. So you need different types of approvals in different types of food markets. And that's the main goal.

Once we can establish all of that with the EPA approval, which we already have in terms of our level of kill rate, then we're golden and these companies can start really implementing us facility-wide.

John Nelson: Okay. And then there's been a major national outbreak of measles across the country. It's one of the most contagious, if not the most contagious, viruses in existence. And I wondered if there's been any interest -- and I know that it's spread not only through the air, but also by surface contact. So I was curious if there was any potential business to be generated from the measles prevention concept?

Halden Shane: No, John, I think there is. I don't think we're there yet with it. Possibly a lot of the states that use our equipment are prepared for it. Right now, I think there's like 5,000 cases, if I remember right, that have been confirmed. If it becomes a real significant number, then you would start using it and trying to decrease the airborne particle of the virus itself. So we'll keep an eye on it. I'm not sure personally that we've been contacted. I know that Pennsylvania is the current center of this outbreak. And we'll get back to everybody publicly if we do hear, and we are hired by any of the states to help with this.

John Nelson: Yes. The biggest concern seems to be infant death. And I was thinking just whether the hospitals might express some interest in any forms of prevention possible.

Halden Shane: They should. I mean all the hospitals have special pathogen units, and some of them even have our equipment in their special pathogen units. And this is -- would be considered to be a special pathogen if it comes in, especially in the child because it does lead to severe complications, pneumonia, brain death, et cetera. That's pretty severe.

John Nelson: Yes. And then, has there been any progress on usage of SteraMist and prevention for honeybees and the treatment of hives to prevent that -- what is it the wingless disease?

Halden Shane: It's a wing [ mite ] that affects a disease in honeybees. And this is a favorite topic of mine. And I hopefully -- we're working with some of the agencies. I know one wanted to do a study on the colonies, but it was very, very expensive for us at the time with everything we have going on. But this mite needs to be killed. Otherwise, it's going to be a big problem for the world. And we believe that we can kill the mite and not damage the queen or the colony.

So this would be possibly a great study to be used on farms or in areas where they release a whole bunch of pollinators to pollinate and many of them just can't fly. I'm sure we all -- everybody listening has seen honeybees that are live but are on the ground. And I would say the majority of those can't fly because they have no wings to fly because of the wing mite.

John Nelson: Okay. And then lastly, the -- and this is my opinion, a depressant on your stock price that I think has been occurring for some time, is because of you having this equity line of credit in place with some deleterious items attached to it. Yes. And so my question is how -- if you can tell me, how soon could you eliminate that equity line of credit?

Halden Shane: Well, I mean, right now, it's a secure way for the company to get capital, and we're working very hard on getting capital through other mechanisms, and we're very close. I mean, very close. So it's always good to have because we can depend on it if needed, and it's other areas we're considering. And we're -- again, -- we'll let everybody know when we come across a better deal for capital for the company going forward.

John Nelson: Okay. And if you continue with this significant progress and profitability, you should not have to access credit through this ELOC, correct?

Halden Shane: That's true. That's true. That's true.

Operator: There are no more questions in queue at this time. I would now like to turn the floor back over to management for closing remarks.

Halden Shane: Again, I just want to thank everybody for your attendance and listening to our delivery. And I hope to speak in the very near future at our next presentation. Have a wonderful time wherever you might be. And thank you.

Operator: Thank you, everyone. This does conclude today's conference call. You may disconnect your phone lines at this time, and have a wonderful day. Thank you for your participation.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.